Increased coronary heart disease risk determined by high high-density lipoprotein cholesterol and c-reactive protein: Modulation by variation in the CETP gene

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 8, 2010, Pages 1502-1503

  Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CORONARY ARTERY DISEASE; CORONARY RISK; EDITORIAL; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, GENETIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 77955168119     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.209544     Document Type: Editorial

References (16)

1. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-1839.
2. Barter P, Gotto AM, LaRosa JC, Maroni J, M. Szarek M, Grundy SM, Kastelein JJ, V. Bittner V, Fruchart JC. Treating to new targets investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
3. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49-55.
4. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193-205.
5. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798.
6. Van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634-642.
7. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF. HDL inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest. 2010;40:483-489.
8. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis. 2006;187:191-197.
9. Dullaart RPF, Sluiter WJ. Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis. Pharmacogenomics. 2008;9:747-763.
10. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RPF, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-2788.
11. Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Sparks CE. CETP polymorphism (TaqIB) associates with risk in postinfarction patients with high HDL cholesterol and high CRP levels. Arterioscler Thromb Vasc Biol. 2010;30:1657-1664.
12. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009;58:2711-2717.
13. Dullaart RPF, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta. 2010;1801:84-88.
14. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RPF. PREVEND study group. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab. 2006;91:3382-3388.
15. van Acker BA, Botma GJ, Zwinderman AH, Kuivenhoven JA, Dallinga-Thie GM, Sijbrands EJ, Boer JM, Seidell JC, Jukema JW, Kastelein JJ, Jansen H, Verhoeven AJ. REGRESS study group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. Atherosclerosis. 2008;200:161-167.
16. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, Zwinderman AH, Kuivenhoven JA, Zwinderman AH, van der Graaf Y, Bots ML, Doevendans PA. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29:2792-2799.